GC Biopharma Corp.

KOSE:A006280 Stock Report

Market Cap: ₩1.9t

GC Biopharma Valuation

Is A006280 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A006280 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A006280 (₩167600) is trading above our estimate of fair value (₩113076.76)

Significantly Below Fair Value: A006280 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A006280?

Key metric: As A006280 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A006280. This is calculated by dividing A006280's market cap by their current revenue.
What is A006280's PS Ratio?
PS Ratio1.2x
Sales₩1.64t
Market Cap₩1.93t

Price to Sales Ratio vs Peers

How does A006280's PS Ratio compare to its peers?

The above table shows the PS ratio for A006280 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average25.8x
A298380 ABL Bio
40.9x25.5%₩1.3t
A007390 NatureCellLtd
45.7xn/a₩1.3t
A145020 Hugel
8.4x17.3%₩3.0t
A214450 PharmaResearch
8.5x24.2%₩2.7t
A006280 GC Biopharma
1.2x9.1%₩1.9t

Price-To-Sales vs Peers: A006280 is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (25.8x).

Price to Sales Ratio vs Industry

How does A006280's PS Ratio compare vs other companies in the KR Biotechs Industry?

26 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.10.7x39.0%
A006280 GC Biopharma
 1.2x9.1%US$1.33b
A096530 Seegene
2.7x15.7%US$748.81m
A086900 Medy-Tox
3.5x14.2%US$580.95m
A006280 1.2xIndustry Avg. 10.7xNo. of Companies26PS01632486480+
26 CompaniesEstimated GrowthMarket Cap
Industry Avg.10.7x82.6%
A006280 GC Biopharma
 1.2x96.6%US$1.33b
No more companies

Price-To-Sales vs Industry: A006280 is good value based on its Price-To-Sales Ratio (1.2x) compared to the KR Biotechs industry average (10.7x).

Price to Sales Ratio vs Fair Ratio

What is A006280's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A006280 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio2.6x

Price-To-Sales vs Fair Ratio: A006280 is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A006280 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩167,600.00
₩201,285.71
+20.1%
3.3%₩210,000.00₩189,000.00n/a7
Dec ’25₩151,000.00
₩198,428.57
+31.4%
3.3%₩210,000.00₩189,000.00n/a7
Nov ’25₩152,200.00
₩195,000.00
+28.1%
6.5%₩210,000.00₩170,000.00n/a6
Oct ’25₩151,500.00
₩176,666.67
+16.6%
10.2%₩200,000.00₩150,000.00n/a6
Sep ’25₩170,900.00
₩167,428.57
-2.0%
9.4%₩200,000.00₩150,000.00n/a7
Aug ’25₩144,400.00
₩158,666.67
+9.9%
5.7%₩170,000.00₩150,000.00n/a6
Jul ’25₩115,800.00
₩146,333.33
+26.4%
3.1%₩150,000.00₩140,000.00n/a6
Jun ’25₩114,700.00
₩146,333.33
+27.6%
3.1%₩150,000.00₩140,000.00n/a6
May ’25₩114,300.00
₩144,666.67
+26.6%
3.3%₩150,000.00₩140,000.00n/a6
Apr ’25₩123,300.00
₩145,000.00
+17.6%
3.4%₩150,000.00₩140,000.00n/a6
Mar ’25₩117,900.00
₩146,428.57
+24.2%
4.0%₩155,000.00₩140,000.00n/a7
Feb ’25₩109,900.00
₩146,428.57
+33.2%
4.0%₩155,000.00₩140,000.00n/a7
Jan ’25₩125,500.00
₩146,428.57
+16.7%
6.5%₩160,000.00₩130,000.00n/a7
Dec ’24₩114,900.00
₩147,857.14
+28.7%
7.2%₩160,000.00₩130,000.00₩151,000.007
Nov ’24₩97,800.00
₩149,285.71
+52.6%
6.8%₩160,000.00₩130,000.00₩152,200.007
Oct ’24₩108,700.00
₩156,428.57
+43.9%
2.8%₩160,000.00₩150,000.00₩151,500.007
Sep ’24₩113,000.00
₩156,428.57
+38.4%
2.8%₩160,000.00₩150,000.00₩170,900.007
Aug ’24₩114,500.00
₩156,428.57
+36.6%
2.8%₩160,000.00₩150,000.00₩144,400.007
Jul ’24₩114,800.00
₩159,857.14
+39.2%
6.9%₩180,000.00₩140,000.00₩115,800.007
Jun ’24₩128,500.00
₩158,625.00
+23.4%
6.8%₩180,000.00₩140,000.00₩114,700.008
May ’24₩123,600.00
₩159,888.89
+29.4%
6.7%₩180,000.00₩140,000.00₩114,300.009
Apr ’24₩122,100.00
₩164,250.00
+34.5%
6.7%₩180,000.00₩150,000.00₩123,300.008
Mar ’24₩119,800.00
₩171,750.00
+43.4%
10.1%₩210,000.00₩150,000.00₩117,900.008
Feb ’24₩131,700.00
₩176,750.00
+34.2%
8.2%₩210,000.00₩160,000.00₩109,900.008
Jan ’24₩129,500.00
₩176,750.00
+36.5%
8.2%₩210,000.00₩160,000.00₩125,500.008
Dec ’23₩129,000.00
₩184,555.56
+43.1%
14.1%₩247,000.00₩160,000.00₩114,900.009

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 07:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GC Biopharma Corp. is covered by 27 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
In Pil KimCape Investment & Securities Co., Ltd.
David LeeCLSA
Sunghwan KimCredit Suisse